Last week the UK’s CMA published a proposal submitted by Illumina and PacBio to save their merger. This was then published in a revised, seemingly more generous form on Wednesday. Most strikingly, the proposal tackles head-on an elephant long in the room: is the CMA playing hardball because the biggest competitor in this space is not named Oslo Nanopore Technologies.
A computational biologist's personal views on new technologies & publications on genomics & proteomics and their impact on drug discovery
Thursday, November 21, 2019
Wednesday, November 20, 2019
Today Genapsys launches their sequencer into the U.S. market, with worldwide launch next year. They also received a new round ($90M) of financing from a major firm, Foresite Capital. In addition to the Press Release and Media Kit, Genapsys' PR team, provided me with answers to a set of questions I provided. As a reminder, I previously covered their pre-print pushed out to BioRxiv six months ago.
Subscribe to: Posts (Atom)